Aktualʹnaâ Infektologiâ (Feb 2020)

Bactoblis® (Streptococcus salivarius K12) — innovative therapy and prevention of acute respiratory infections and their complications

  • S.A. Kramarev,
  • V.V. Yevtushenko

DOI
https://doi.org/10.22141/2312-413x.8.1.2020.196172
Journal volume & issue
Vol. 8, no. 1
pp. 50 – 53

Abstract

Read online

The action of Streptococcus salivarius K12 (Bacto­blis®) is due to the colonization of the oral cavity and nasopha­rynx, that is, it is a respiratory probiotic. Streptococcus saliva­rius K12 actively inhibits the growth of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae and Mora­xella catarrhalis, which are among the main etiological factors of bacterial infections of the respiratory tract in children. Clinical studies are reviewed, their results confirm the efficacy and safety of Bactoblis® in the pediatric population with recurrent streptococcal infections of the upper respiratory tract. It emphasizes the importance of Streptococcus salivarius K12 admi­nistration after taking antibiotic therapy to restore the natural microbiocenosis of the oral cavity, nasopharynx, and to reduce antibiotic resistance.

Keywords